Recent

% | $
Quotes you view appear here for quick access.

Genomic Health Inc. Message Board

  • terry_amln terry_amln Sep 25, 2012 5:51 AM Flag

    Analysts on GHDX / Piper reiterates overweight rating

    Piper Jaffray reaffirmed their overweight rating on shares of Genomic Health (NASDAQ: GHDX) in a research note

    Several other analysts have also recently commented on the stock. Analysts at Zacks downgraded shares of Genomic

    Health from an outperform rating to a neutral rating in a research note to investors on Friday, August 17th. They now have a $38.00 price target on the stock.

    Separately, analysts at Bank of America initiated coverage on shares of Genomic Health in a research note to investors on Thursday, August 16th. They set a buy rating and a $44.00 price
    target on the stock.

    Genomic Health last released its earnings data on Wednesday, August 8th. The company reported $0.06 EPS for thequarter, beating the Thomson Reuters consensus estimate of ($0.02) by $0.08. The company’s revenue for the quarterwas up 13.4% on a year-over-year basis.

    Genomic Health, Inc. (Genomic Health) is a molecular diagnostics company focused on the development and global commercialization of genomic-based clinical laboratory services , which analyzes the underlying biology of cancer,allowing physicians and patients to make individualized treatment decisions

    Good Luck

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
GHDX
30.21+0.55(+1.85%)Mar 27 4:00 PMEDT